Predictive Preclinical Models in Oncology
Reporter: Aviva Lev-Ari, PhD, RN
PRELIMINARY AGENDA JUST RELEASED
Predicting whether a potential new anticancer agent will be effective in patients remains a challenge. Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in Phase III clinical trials. This situation brings into question the quality of preclinical tumor models and predictability of preclinical studies in oncology. There is a critical need for models and approaches that allow to more effectively evaluate novel cancer therapeutics as well as to identify predictive biomarkers early in drug development. CHI’s Third Annual Predictive Preclinical Models in Oncology is designed to highlight the cutting-edge in vitro and in vivo preclinical tumor models and to facilitate a discussion about effective translational approaches in cancer research.
ADVANCES IN TUMOR MODELING – ADVANCES IN CANCER DRUG DISCOVERY AND DEVELOPMENT
Assessing The Predictive Value of Preclinical Cancer Models
Alexander Kamb, Ph.D., Senior Vice President, Discovery Research, Amgen
Targeting Developmental Pathways in Cancer
Frederic de Sauvage, Ph.D., Vice President, Molecular Oncology, Genentech
Preclinical Trials in Mouse Models of Brain Tumors
Eric C. Holland, M.D., Ph.D., Senior Vice President, Director, Division of Human Biology, Solid Tumor Translational Research, Nancy and Buster Alvord Brain Tumor Center, Fred Hutchinson Cancer Research Center, University of Washington
Microenvironmental Regulation of GBM Progression and Therapeutic Resistance
Gabriele Bergers, Ph.D., Professor of Neurological Surgery, Neill H. and Linda S. Brownstein Endowed Chair in Brain Tumor Research, Principal Investigator, Brain Tumor Research Center, University of California, San Francisco
Towards Personalized Medicine: Companion Therapeutics in the I-SPY 2 TRIAL
Laura J. van’t Veer, Ph.D., Professor of Laboratory Medicine, University of California San Francisco; Leader, Breast Oncology Program; Associate Director, Applied Genomics, UCSF Helen Diller Family
TRANSLATIONAL APPROACHES IN CANCER IMMUNOTHERAPY DEVELOPMENT
Biomarkers in Cancer Immunotherapy
Ira Mellman, M.D., Vice President, Cancer Immunology, Genentech
Strategies for Clinical Development of Cancer Immunotherapy
Roy Baynes, M.D., Senior Vice President Global Clinical Development, Merck
Translational Strategies for the Clinical Development of Immunomodulatory Antibodies
Robert Pierce, M.D., CMO, OncoSec Medical, Inc.
Preclinical Validation of Immunotherapies and Combination Strategies for Cancer
James Smothers, Ph.D., Senior Director, Head, Discovery, Immuno-Oncology & Combinations DPU, Oncology R&D, GlaxoSmithKline
UNFOLDING CANCER IMMUNOTHERAPY MECHANISMS
Inflammation and Cancer: Immune Cells as Targets For Anti-Cancer Therapy
Lisa M. Coussens, Ph.D., Professor and Chair, Director, Basic Research, Department of Cell & Developmental Biology, Knight Cancer Institute, Oregon Health & Sciences University
Criteria for Identifying Responses to Cancer Immunotherapy
Alan L. Epstein, M.D., Ph.D., Department of Pathology, USC Keck School of Medicine, Los Angeles
How to Unleash Anti-Tumor Immunity by Modulating the PI3K Pathway
Khaled Ali, Ph.D., Senior Scientist, Amgen Oncology
TRANSLATIONAL APPROACHES TO CHILDHOOD CANCER
Preclinical Childhood Cancer Models for Developing Molecularly Targeted Therapies.
Peter Houghton, Ph.D., Director, Center for Childhood Cancer, The Research Institute, Nationwide Children’s Hospital
The Institutes for Molecular Medicine at Phoenix Children’s Hospital to Address the Unmet Need: Slow Progress in Pediatric Drug Development
Nazneen Aziz, Ph.D., Senior Vice President & Chief Research Officer, Phoenix Children’s Hospital
3D MODELS AND THEIR APPLICATIONS
Evaluating Lymphocyte Redirection and Recruitment Using a Novel 3D Lung Tumor Model System
David Colter, Ph.D., Principal Scientist, Biologics Research, Janssen
ADVANCES IN MODELING AND MODELS’ APPLICATIONS
Preclinical Models of Human Cancer at the Center for Advanced Preclinical Research (CAPR): Quantitative Methods for Assaying Drug Efficacy and Resistance
Philip Martin, Ph.D., D.V.M., Veterinary Pathologist, Center for Advanced Preclinical Research (CAPR), Frederick NationalLeidos Biomedical/Laboratory for Cancer Research
Validation of a Tumor Antigen Also Expressed on Subsets of Activated Lymphocytes as a T Cell Engager BiTE® Therapy Target
Olivier P. Nolan-Stevaux, Ph.D., Senior Scientist, Department of Oncology, Amgen, Inc.
Patient Derived Xenograft Clinical Trial Program
Neal Goodwin, Ph.D., Vice President, Corporate Research and Development, Champions Oncology
Suggested Event Package:
February 16 Morning Short Course:
Using PDX and Other Preclinical Models in Oncology to Inform First-Man-Trial Design: Tools and Techniques
February 19-20 Symposia:
Cancer Immunotherapy
VIEW conference agenda
register today
For Exhibitor and Sponsorship opportunities, contact:
————————————————————————
Companies A-K
Jon Stroup
Business Development Manager
781-972-5483
Companies L-Z
Joseph Vacca
Business Development Manager
781-972-5431
SOURCE
From: Preclinical Models in Oncology Conference <pete@healthtech.com>
Date: Thu, 04 Sep 2014 16:10:25 -0400
To: <avivalev-ari@alum.berkeley.edu>
Subject: Preliminary Agenda Now Available – Predictive Preclinical Models in Oncology
Leave a Reply